Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT05254899Phase 2Completed
A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)
Early-stageExtranodal NK-T-Cell LymphomaHigh-Risk Cancer
PrincipalinvestigatorStart date: 2021-11-10

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Chinese Academy of Medical Sciences

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Michael Lock, MD

London Health Sciences Centre/London Regional Cancer Program

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Jingao Li

Jiangxi Provincial Cancer Hospital

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Patrick Strentz, MD

General Practioner, Colmar, France

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Mohamed Zaghloul, MD

mszagh@yahoo.com

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Mikhail Fedyanin, MD, PhD, professor

FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Joe Stephenson, MD

Prisma Health-Upstate

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Svetlana Khokhlova, MD, PhD

FSBI "National medical research center for obstetrics, gynecology and perinatology named after academician VI Kulakov" Ministry of healthcare of the Russian Federation

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Rong Tao, MD & PhD

Shanghai Cancer Center

Related
2 trials

Shared therapeutic areas:

Extranodal NK/T-cell Lymphoma
Similarity Score10%

Alexey Tryakin, MD, PhD, professor

FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia

Related
1 trials

Shared therapeutic areas:

High-Risk Cancer
Similarity Score10%

Ye-Xiong Li, MD

CAMS

Related
1 trials

Shared therapeutic areas:

Early-stage

Worked with same sponsors:

The First Hospital of Jilin University
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT05254899Phase 2PrincipalInvestigator

A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)

Early-stageExtranodal NK-T-Cell LymphomaHigh-Risk Cancer
Completed

All 1 trials loaded